Skip to main content

Table 1 Demographics and clinical characteristics of 10 patients with BRAF mutation- positive melanoma

From: Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance

Variable

Group

No. of patients

%

(n = 10)

Age, years

Median

52

 
 

Range

23-60

 
 

<50

5

50

 

≥50

5

50

Sex

Men

7

70

 

Women

3

30

Race

Caucasian

10

100

Number of prior therapies

Median

2

 
 

Range

0-5

 
 

≤2

8

80

 

>2

2

20

Lactate dehydrogenasea

≤upper limit of normal

9

90

 

>upper limit of normal

1

10

TNM stage M1c

No

6

60

 

Yes

4

40

ECOG PS

0

5

50

 

1

5

50

Therapy

BRAF inhibitor alone

7

70

 

MEK inhibitor alone

1

10

 

BRAF/MEK inhibitor combination

2

20

Treatment response

Complete response

4

40

 

Partial response

6

60

  1. aUpper limit of normal in our institution = 618 IU/L.
  2. Abbreviations:ECOG Eastern Cooperative Oncology Group, PS Performance Status, TNM tumor, node, metastasis.